Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation
- 1 March 2020
- journal article
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 3,p. 6-12
- https://doi.org/10.33920/med-01-2003-01
Abstract
The article discusses the current state of the use of pharmacogenetic testing in clinical practice in the field of psychiatry, narcology and neurology in the Russian Federation. The active introduction of pharmacogenetic testing in clinical practice contributes to a personalized approach to predicting the pharmacological response to drugs, increasing the safety and effectiveness of pharmacotherapy, complience and the quality of life of patients with neuropsychiatric disorders. In the future, an increase in the availability of pharmacogenetic testing in real clinical practice is expected.Keywords
This publication has 6 references indexed in Scilit:
- 49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled TrialCNS Spectrums, 2019
- Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient carePsychiatry Research, 2015
- Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorderThe Pharmacogenomics Journal, 2013
- Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressantsBritish Journal of Clinical Pharmacology, 2007
- Pharmacogenetics of Antidepressant Medication IntoleranceAmerican Journal of Psychiatry, 2003
- PHARMACOGENETICSBritish Medical Bulletin, 1961